Skip to navigation Skip to content

Generalised myasthenia gravis (gMG) in Pharmaceutical Benefits Scheme (PBS) 012-26020435

This document outlines details of PBS-subsidised ravulizumab and zilucoplan for patients with generalised myasthenia gravis (gMG).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Generalised myasthenia gravis (gMG) quick reference

Table 1

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Acute severe PB394 form	Written Electronic S100: ravulizumab zilucoplan	No	OPA	Must be treated by a prescriber who is a: neurologist clinical immunologist with expertise in the treatment of gMG medical practitioner in consultation with one of the above specialist types	Yes
Bridging therapy PB395 form	Written Electronic S100: ravulizumab zilucoplan	No	OPA	Must be treated by a prescriber who is a: neurologist clinical immunologist with expertise in the treatment of gMG medical practitioner in consultation with one of the above specialist types	Yes
Treatment refractory Initial PB396 form	Written Electronic S100: ravulizumab zilucoplan	No	OPA	Must be treated by a prescriber who is a: neurologist clinical immunologist with expertise in the treatment of gMG medical practitioner in consultation with one of the above specialist types	Yes
Treatment refractory Initial grandfather PB398 form	Written Electronic S100: ravulizumab zilucoplan	No	OPA	Must be treated by a prescriber who is a: neurologist clinical immunologist with expertise in the treatment of gMG medical practitioner in consultation with one of the above specialist types	Yes
Treatment refractory Continuing PB397 form	Written Electronic S100: ravulizumab zilucoplan	No	OPA	Must be treated by a prescriber who is a: neurologist clinical immunologist with expertise in the treatment of gMG medical practitioner in consultation with one of the above specialist types	Yes